{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:00:55Z","timestamp":1792598455487,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Type 2 inflammation is a fundamental immunologic pathway underlying a growing spectrum of dermatologic diseases. While classically associated with atopic dermatitis, type 2 immune responses are increasingly recognized as key contributors to prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid, lichen simplex chronicus, and other chronic pruritic disorders. Barrier disruption and epithelial injury initiate the release of alarmins, including thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25, which activate innate and adaptive immune pathways that promote type 2 inflammation. Subsequent production of effector mediators such as IL-4, IL-13, IL-5, IL-31, immunoglobulin E (IgE), and periostin drives barrier dysfunction, immune cell recruitment, tissue remodeling, and chronic pruritus. Increasing evidence further highlights the importance of neuroimmune crosstalk, with direct interactions between immune cells, cytokines, and sensory neurons contributing to itch sensitization and disease persistence. The clinical success of biologic therapies targeting IL-4\/IL-13, IgE, and IL-31 signaling has provided powerful functional validation of these pathogenic pathways and has transformed the management of multiple inflammatory skin diseases. In this review, we summarize the molecular and cellular mechanisms underlying type 2 inflammation in the skin, discuss its role across diverse dermatologic conditions, and highlight emerging concepts in disease heterogeneity, neuroimmune signaling, and precision medicine. Collectively, these findings support type 2 inflammation as a unifying immunologic framework and therapeutically actionable target across dermatology.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1917593","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:15:56Z","timestamp":1786976156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting type 2 inflammation in dermatology: mechanisms and clinical implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Nicole","family":"Khalil","sequence":"first","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Farhadi","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155664","article-title":"Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans","volume":"148","author":"Nakajima","year":"2021","journal-title":"Cytokine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/all.16620","article-title":"The evolution, immunopathogenesis and biomarkers of type 2 inflammation in common allergic disorders","volume":"80","author":"Gao","year":"2025","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17707","article-title":"Type 2 inflammation and its role in dermatologic diseases","volume":"64","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14401","article-title":"The pruritogenic role of the type 2 immune response in diseases associated with chronic itch","volume":"30","author":"Ingrasci","year":"2021","journal-title":"Exp Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci124606","article-title":"Epithelial cell-derived cytokines: More than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.02.001","article-title":"Neuroimmune mechanisms of type 2 inflammation in the skin and lung","volume":"74","author":"Tamari","year":"2025","journal-title":"Allergol Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: New insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7697699","article-title":"The role of TSLP in atopic dermatitis: From pathogenetic molecule to therapeutical target","volume":"2023","author":"Luo","year":"2023","journal-title":"Mediators Inflammation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211053156","article-title":"Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target","volume":"50","author":"Jin","year":"2022","journal-title":"J Int Med Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12545","article-title":"The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis","volume":"278","author":"Otsuka","year":"2017","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.02.005","article-title":"Mast cell-sensory neuron crosstalk in allergic diseases","volume":"153","author":"Bao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213138","article-title":"Basophils in pruritic skin diseases","volume":"14","author":"Wiebe","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70024","article-title":"IgE-mediated activation of mast cells and basophils in health and disease","volume":"331","author":"Charles","year":"2025","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2024.01.022","article-title":"Basophils are important for development of allergic skin inflammation","volume":"153","author":"Leyva-Castillo","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci58978","article-title":"Periostin promotes chronic allergic inflammation in response to Th2 cytokines","volume":"122","author":"Masuoka","year":"2012","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.03.009","article-title":"Periostin, an emerging player in itch sensation","volume":"141","author":"Hashimoto","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13120","article-title":"The IL-13-Ovol1-FLG axis in atopic dermatitis","volume":"158","author":"Furue","year":"2019","journal-title":"Immunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.09.014","article-title":"Basic mechanisms of itch and advances in clinical management","volume":"136","author":"Coscarella","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/imr.13230","article-title":"Engineering the IL-4\/IL-13 axis for targeted immune modulation","volume":"320","author":"Bernstein","year":"2023","journal-title":"Immunol Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: The \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.011","article-title":"Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch","volume":"156","author":"Jha","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-026-01255-8","article-title":"Cross-talk between neurons and immune cells in pruritus: From mechanisms to medicines","volume":"26","author":"Khalil","year":"2026","journal-title":"Curr Allergy Asthma Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","article-title":"IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin","volume":"151","author":"Hashimoto","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jaci.2017.12.1002","article-title":"New mechanism underlying IL-31-induced atopic dermatitis","volume":"141","author":"Meng","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00422","article-title":"Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation","volume":"13","author":"Siiskonen","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000323299","article-title":"The role of cytokines\/chemokines in the pathogenesis of atopic dermatitis","volume":"41","author":"Yamanaka","year":"2011","journal-title":"Curr Probl Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.13-RAI-0564","article-title":"New insights into atopic dermatitis: Role of skin barrier and immune dysregulation","volume":"62","author":"Leung","year":"2013","journal-title":"Allergol Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3390\/jcm11195633","article-title":"The IL-4\/-13 axis and its blocking in the treatment of atopic dermatitis","volume":"11","author":"Pappa","year":"2022","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/jcm10091906","article-title":"Interleukin-31 and pruritic skin","volume":"10","author":"Furue","year":"2021","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1386","article-title":"Focused update: Guidelines of care for the management of atopic dermatitis in adults","volume":"93","author":"Davis","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01644-3","article-title":"Lebrikizumab improves clinical manifestations, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt study","volume":"16","author":"Silverberg","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879754","article-title":"The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13601-015-0074-7","article-title":"Immunological events in chronic spontaneous urticaria","volume":"5","author":"Ferrer","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.033","article-title":"The pathogenesis of chronic spontaneous urticaria: The role of infiltrating cells","volume":"9","author":"Gim\u00e9nez-Arnau","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2021.13.2.206","article-title":"Total IgE as a marker for chronic spontaneous urticaria","volume":"13","author":"Altrichter","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: Targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1684\/ejd.2024.4600","article-title":"Biomarkers to predict therapeutic response in chronic spontaneous urticaria: A review","volume":"34","author":"Gimenez-Arnau","year":"2024","journal-title":"Eur J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (Liberty-Csu Cupid): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v92iS7.12415","article-title":"Biologic drugs in chronic spontaneous urticaria","volume":"92","author":"Licari","year":"2021","journal-title":"Acta BioMed"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B56","volume-title":"Approved drug Products with Therapeutic Equivalence Evaluations","year":"2026"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/ph17111499","article-title":"Therapies for chronic spontaneous urticaria: Present and future developments","volume":"17","author":"Asero","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1668742","article-title":"The recent advances of mast cells in the pathogenesis of atopic dermatitis","volume":"6","author":"Xiao","year":"2025","journal-title":"Front Allergy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"10720","DOI":"10.3390\/ijms262110720","article-title":"The central role of Th2 immune response in inflammatory dermatoses: From pathogenesis to targeted therapies","volume":"26","author":"Pala","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: Pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111933","article-title":"Periostin activates distinct modules of inflammation and itching downstream of the type 2 inflammation pathway","volume":"42","author":"Nunomura","year":"2023","journal-title":"Cell Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2340\/actadv.v106.adv-2025-0169","article-title":"Comprehensive transcriptomic profiling of nonatopic prurigo nodularis in Korean patients reveals Il-22-driven epidermal stress and neuro-immuno-fibrotic remodelling","volume":"106","author":"Kim","year":"2026","journal-title":"Acta Derm Venereol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1011142","article-title":"Circulating plasma Il-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis","volume":"9","author":"Parthasarathy","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: The Olympia 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: The role of complement-independent mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02992-w","article-title":"Pathophysiology of bullous pemphigoid: Role of type 2 inflammation and emerging treatment strategies (narrative review)","volume":"41","author":"Werth","year":"2024","journal-title":"Adv Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1651543","article-title":"Dupilumab treatment outcomes in bullous pemphigoid: A systematic review and single-arm meta-analysis","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: An ambispective multicentre case series","volume":"192","author":"Planella-Fontanillas","year":"2025","journal-title":"Br J Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad432","article-title":"Omalizumab therapy of bullous pemphigoid","volume":"190","author":"Fairley","year":"2024","journal-title":"Br J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70259","article-title":"Pathogenesis and therapeutics for chronic pruritus of unknown origin: A systematic review","volume":"65","author":"Akiska","year":"2026","journal-title":"Int J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1177\/1177271920940712","article-title":"Interleukin-31 and chronic pruritus of unknown origin","volume":"15","author":"Salao","year":"2020","journal-title":"biomark Insights"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.17342241","article-title":"Wells syndrome: Clinical presentation and literature review","volume":"63","author":"Vega-Del Pilar","year":"2025","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.206","article-title":"Atypical Wells syndrome successfully treated with dupilumab","volume":"3","author":"McMullan","year":"2023","journal-title":"Skin Health Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.02.011","article-title":"Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab","volume":"4","author":"Herout","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00403-025-04305-9","article-title":"Wells syndrome: Emerging triggers and treatments- an updated systematic review","volume":"317","author":"Ahmed","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17158","article-title":"Eosinophilic annular erythema successfully treated with dupilumab: A case report","volume":"51","author":"Okazaki","year":"2024","journal-title":"J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13533","article-title":"Eosinophilic annular erythema treated with dupilumab","volume":"35","author":"Gordon","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-025-00979-z","article-title":"Lichen simplex chronicus: Clinical perspectives and emerging therapeutic strategies","volume":"26","author":"Moshkovich","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.4367","article-title":"Lichen simplex chronicus itch: An update","volume":"102","author":"Ju","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00149-x","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/00313020802320739","article-title":"Evaluation of the profile of the immune cell infiltrate in lichen planus, discoid lupus erythematosus, and chronic dermatitis","volume":"40","author":"Hussein","year":"2008","journal-title":"Pathology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted Il-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: A French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: A review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"Jama"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.06.004","article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis","volume":"156","author":"Chu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: Results from the phase Iib multinational randomized double-blind placebo-controlled Arroyo trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/all.15056","article-title":"From dream to Realiti-a and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (Arcadia 1 and Arcadia 2): Results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","article-title":"Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells","volume":"15","author":"Bangert","year":"2024","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/jcm15041525","article-title":"Dupilumab-related hypereosinophilia in patients treated for type 2 diseases: Evidence from a 24-month prospective real-life study","volume":"15","author":"Mormile","year":"2026","journal-title":"J Clin Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2026.05.027","article-title":"Safety of remibrutinib in chronic spontaneous urticaria: A pooled analysis of Remix-1 and Remix-2 trials","author":"Gim\u00e9nez-Arnau","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2022.12.e20","article-title":"Treatment-resistant atopic dermatitis: Novel therapeutics, digital tools, and precision medicine","volume":"12","author":"Naik","year":"2022","journal-title":"Asia Pac Allergy"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501135","article-title":"Precision medicine and treat-to-target approach in atopic dermatitis: Enhancing personalized care and outcomes","volume":"100","author":"Hartmann","year":"2025","journal-title":"Bras Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2025.05.007","article-title":"Dissecting key contributions of T(H)2 and T(H)17 cytokines to atopic dermatitis pathophysiology","volume":"156","author":"Meesters","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.010","article-title":"Neuroimmune communication regulating pruritus in atopic dermatitis","volume":"149","author":"Steinhoff","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.076","article-title":"Beyond T helper 2 cells: Integrating immune, barrier, microbial, and neuroimmune pathways in atopic dermatitis pathogenesis","volume":"94","author":"Zhou","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.057","article-title":"Emerging treatments for itch in atopic dermatitis: A review","volume":"89","author":"Labib","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1907341","article-title":"The emerging role of dupilumab in dermatological indications","volume":"21","author":"Napolitano","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2612882","article-title":"Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: A systematic review and synthesis of emerging evidence","volume":"37","author":"Shanshal","year":"2026","journal-title":"J Dermatol Treat"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1471","article-title":"Nemolizumab for cholestatic pruritus in a patient with liver transplant and primary sclerosing cholangitis","volume":"161","author":"Soto-Canetti","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874108","article-title":"Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: A case series of 13 patients","volume":"13","author":"Alexandre","year":"2022","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-026-02292-3","article-title":"Autoimmune bullous diseases: Therapeutic update","volume":"86","author":"Kasperkiewicz","year":"2026","journal-title":"Drugs"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:16:01Z","timestamp":1786976161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2026.1917593"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1917593","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1917593"}}